Full Breakdown
New Bacterial Species Linked to Noma in Nigerian Children
4/25/2026, 9:51:41 PM
Discovery of Treponema A in Noma Lesions
Prof Adam Roberts (Liverpool School of Tropical Medicine) led the study with Angus O’Ferrall. Co-authors were University of Liverpool, Médecins Sans Frontières and Noma Children’s Hospital, Nigeria. Treponema A was found in most of 19 patients; estimates place noma incidence at tens of thousands of cases annually with 90 % fatality rate without treatment.
Noma: Disease Overview
Noma begins as a painful gum ulcer that can quickly destroy jaw, mouth and facial tissues. Without prompt treatment it is fatal in 90 % of cases; survivors often suffer facial scarring and stigma. The disease mainly affects children, especially in Sahel, where estimates suggest tens of thousands of cases annually. Antibiotics can halt progression, yet microbial cause remains unknown.
Study Team, Findings and Epidemiology
The research was coordinated by Prof Adam Roberts, senior author, with contributions from the University of Liverpool, Médecins Sans Frontières and the Noma Children’s Hospital in Sokoto, Nigeria. The pilot data show Treponema A in the majority of the 19 examined children, while global estimates place noma incidence at tens of thousands of cases each year with a 90 % fatality rate without treatment.
Official Statements & Responses
Prof Adam Roberts described the discovery as a great reveal and expressed astonishment at detecting a new bacterium in noma lesions. He said causality remains uncertain—Treponema A may cause or merely colonise the wound—and suggested a diagnostic test could enable prophylactic antibiotics. Dr Michael Head called the results a useful first step to understanding a mysterious condition, and Prof Philippe Guérin called the work a valuable starting point for research and funding.
Criticism, Uncertainties and Gaps
The small sample size and single-country focus limit confidence in findings’ generalisability. Researchers note Treponema A could be an opportunistic coloniser rather than primary cause. Epidemiological data on noma are scarce, with case numbers based on expert estimates, not surveillance. These gaps call for larger, multi-country studies with healthy community controls to clarify causality and evaluate diagnostics and treatments.
Verbatim Quotes
- “a great reveal” — Prof Adam Roberts, Senior Author, Liverpool School of Tropical Medicine
- “We don’t know causality,” — Prof Adam Roberts, Senior Author, Liverpool School of Tropical Medicine
- “At the moment, the only thing that we have is a clinical diagnosis based on symptoms.” — Prof Adam Roberts, Senior Author, Liverpool School of Tropical Medicine
What’s Next: Larger Study and Diagnostic Development
Investigators plan a multi-country follow-up that will sample noma patients and healthy children to determine prevalence of Treponema A and its relationship to disease onset. Parallel work aims to create a rapid molecular test for Treponema A in gingivitis, enabling prophylactic antibiotics and reducing reliance on broad-spectrum drugs. Researchers also propose probiotic interventions to restore healthy oral flora and mitigate antimicrobial-resistance risks.
